MDGL: 28% | Madrigal Pharmaceuticals shares are trading higher after the company announced FDA approval of Rezdiffra for the treatment of patients with noncirrhotic NASH with moderate to advanced liver fibrosis.
CLDX: 53% | Cardlytics shares are trading higher after the company reported better-than-expected Q4 revenue results and issued Q1 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $12 to $15.
ADBE: -12% | Adobe shares are trading lower after the company reported Q1 financial results and issued weak guidance. Also, multiple firms lowered their respective price targets on the stock.